Share Twitter LinkedIn Facebook Email Fumito Ito, MD, PhD of Roswell Park @RoswellPark discusses CX3CR1–CD8+ T cells are critical in antitumor efficacy but functionally suppressed in the tumor microenvironment. Read here: https://insight.jci.org/articles/view/133920?utm_source=Cision&utm_medium=Email&utm_term=Apr-20%60&utm_content=cancer%2c+melanoma%2c+prostate%2c+pancreatic%2c+rectal%2c+treatment%2c+studies%2c+research
FDA Approves Deciphera Vimseltinib / Romvimza for symptomatic tenosynovial giant cell tumor (TGCT) patients Other 2 Mins Read
FDA Approves Mirdametinib: Is this the Breakthrough NF1-PN Patients Have Been Waiting For? Other 3 Mins Read
Understanding and Managing BPDCN: Insights from Priyanka Meta’s Conference Presentation Other 2 Mins Read
